Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants
Status:
Terminated
Trial end date:
2017-10-30
Target enrollment:
Participant gender:
Summary
A multi-center, open-label, single-arm clinical study to assess effects of a 5-day regimen of
10 micrograms per kilogram (mcg/kg) of tbo-filgrastim administered subcutaneously daily on
the mobilization of cluster of differentiation 34+ (CD34+) cells in at least 60 healthy male
and female participants. The pharmacokinetics, pharmacodynamics, safety, tolerability, and
immunogenicity of tbo-filgrastim will be assessed.